A German study has revealed that the health damage from cannabis legalisation substantially exceeds any purported benefits, with harms outweighing advantages by nearly 20 to one.

The research, published in the science journal PLOS, represents one of the first attempts to quantify the trade-off between health risks and benefits associated with marijuana legalisation. The findings arrive as Ireland prepares fresh hearings on potential drug law reforms.

Quantifying the True Cost of Legalisation

Conducted by Afschin Gandjour of the Frankfurt School of Finance & Management, the German cannabis study examined the country’s 2024 legalisation, which permitted limited access through cannabis clubs and home cultivation whilst excluding commercial sales.

The analysis paints a troubling picture. Researchers estimated that harms from use disorder proved “approximately 19 times greater” than health gains from reduced contamination of illegal products.

This disparity emerged despite Germany implementing a relatively restrictive model, far more limited than Canada’s commercial approach. The finding suggests that even cautious legalisation frameworks cannot prevent serious public health consequences.

Mental Health Crisis Looms Large

The German cannabis study projected an increase of 400,000 to 800,000 new adult users following legalisation, representing 10-20% growth amongst Germany’s four million existing users.

Most alarmingly, analysts estimated that 1-2% of new users may develop long-term mental health problems. This translates to approximately 2,300 additional cases of severe conditions, including depression and psychosis.

These figures underscore concerns that have troubled medical professionals for years. Whilst supporters emphasise contamination risks in black market products, the study suggests these dangers pale in comparison to harms created by increased legal access.

The Black Market Paradox

The research identified a tension in legalisation policy: the conflict between reducing illegal markets and preventing increased consumption.

“There is a clear conflict between the goal of reducing the black market and the risk of promoting more consumption,” the report stated. “The challenge for policymakers is to find a balance between these objectives by regulating the market effectively without unnecessarily increasing consumption.”

Researchers warned that efforts to completely eliminate illegal cannabis markets through legalisation may come “at the expense of public health, namely, through increased consumption and related harms.”

The PLOS research noted that consumers’ desire for convenient access fails to account for broader societal damage, including health risks, addiction, and escalating healthcare costs.

Regulatory Recommendations

Despite the sobering findings from the German cannabis study, researchers suggested that “careful regulation” could potentially reduce some risks. Recommended measures include:

• Regulation of THC potency levels
• Targeted public health campaigns
• Strategic taxation to discourage overuse, though not so high as to drive consumers back to illegal sources

The potency issue carries particular weight. Previous research has demonstrated that THC concentrations in cannabis products have increased substantially over recent decades, with some dispensary offerings now containing over 40% THC, far exceeding historical levels.

Implications for Irish Drug Policy

The findings arrive at a critical moment for Ireland, where the Oireachtas drugs committee is preparing to resume public hearings on potential drug law changes this month.

The first committee examined recommendations from the Citizens Assembly on Drugs, which published its report in January 2024, and issued an interim report last October before the general election. However, the second committee has held no public sessions since the new government formed in January.

The German cannabis study provides important data for Irish policymakers grappling with similar questions. The quantification of health trade-offs offers evidence that cannot be easily dismissed.

A Cautious Path Forward

The research challenges assumptions that legalisation represents a straightforward harm-reduction strategy. Whilst eliminating contaminated black market products delivers measurable benefits, these gains appear minimal compared to increased mental health problems, addiction cases, and associated healthcare burdens.

For policymakers worldwide, the message is clear: legalisation frameworks must prioritise public health protection over market elimination or consumer convenience. The German experience suggests that even restricted legalisation models carry substantial risks.

As Ireland and other nations contemplate cannabis policy reforms, the PLOS research provides necessary context. The health implications of legalisation extend far beyond individual choice. They encompass broader societal costs that demand careful consideration.

The study’s authors emphasised that striking the right regulatory balance requires acknowledging uncomfortable truths. Easy access may satisfy consumer demands, but the price, measured in mental health crises, addiction, and healthcare costs, raises serious questions about whether legalisation serves the public interest.

Source: Irish Examiner